Skip to main content

Table 1 Main characteristics of studies included in the meta-analysis

From: Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies

First author, year of publication, and reference Patient country of origin Dominant ethnicity Study design Malignant disease Main type of pathology Detected sample Survival analysis Source of HR Maximum follow-up, months
Lee, 2013 [5] USA White R Brain glioma Glioblastoma Tissue OS Reported 120
Saija, 2013 [6] Finland White R Brain glioma Glioblastoma Tissue OS SC 135
Campayo, 2013 [7] Spain White R NSCLC Adeno/SCC Tissue RFS SC 36
Yu, 2013 [11] China Asian R HNC SCC Tissue OS SC 60
Avgeris, 2013 [20] Greece White R Prostate cancer Adeno Tissue DFS Reported 72
Tang, 2013 [21] China Asian R Osteosarcoma Sarcoma Tissue OS/DFS Reported 152
Tanaka, 2013 [22] Japan Asian R Esophageal cancer SCC Serum PFSa SC 39
Speranza, 2012 [23] Italy White R Brain glioma Glioblastoma Tissue OS SC 18
Kang, 2012 [24] Korea Asian R Prostate cancer Adeno Tissue RFS Reported 55
Schee, 2012 [25] Norway White R CRC Adeno Tissue MFS SC 60
Law, 2012 [9] China Asian R HCC Adeno Tissue DFS SC 144
Ko, 2012 [12] Canada White R Esophageal cancer SCC Tissue DFS SC 32
Huang, 2012 [26] China Asian R Cervical cancer Small cell carcinoma Tissue OS SC 70
Marchini, 2011 [27] Italy White R EOC Adeno Tissue OS/PFS Reported 143
Radojicic, 2011 [28] Greece White R Breast cancer Adeno Tissue OS/DFS SC 120
Leite, 2011 [13] Brazil White R Prostate cancer Adeno Tissue RFS Reported 122
Hamano, 2011 [29] Japan Asian R Esophageal cancer SCC Tissue OS SC 97
Drebber, 2011 [30] Germany White R Rectal cancer Adeno Tissue OS SC 72
  1. Adeno, adenocarcinoma; CRC, colorectal cancer; DFS, disease-free surviva; EOC, epithelial ovarian cancer; HCC, hepatocellular carcinoma; HNC, head and neck cancer; HR, hazard ratio; MFS, metastasis-free survival; NSCLC, non-small cell lung cancer; OS, overall survival; P, prospective; PFS, progression-free survival; R, retrospective; RCC, renal cell carcinoma; RFS, relapse-free survival; SC, survival curve; SCC, squamous cell carcinoma.
  2. aPFS included any of the following: DFS, MFS or RFS.